Boston Scientific reported $5.065 billion in net sales for the third quarter of 2025, driven largely by demand for cardiovascular devices.
The company’s cardiovascular segment grew 22.4% year over year on a reported basis, with strong performance from both cardiology and peripheral interventions. U.S. sales rose 27% overall, according to an Oct. 22 news release.
GAAP net income attributable to common stockholders reached $755 million, or $0.51 per share, up from $469 million and $0.32 per share a year prior. Adjusted earnings were $0.75 per share.
The devicemaker also raised its full-year guidance, projecting adjusted earnings of $3.02 to $3.04 per share and organic sales growth of 15.5%.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.